Lenka Besse Selected Research

Multiple Myeloma

1/2022	Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
1/2022	The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
1/2022	Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.
10/2021	Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma.
10/2021	High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors.
7/2021	Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells.
1/2021	Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs.
1/2021	Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.
3/2020	Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.
11/2019	HIV protease inhibitors for the treatment of multiple myeloma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lenka Besse Research Topics

Disease

15	Multiple Myeloma 01/2022 - 01/2015
8	Neoplasms (Cancer) 01/2022 - 08/2015
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 10/2021
2	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 10/2017
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022
1	Plasma Cell Leukemia 01/2022
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 10/2021
1	Fibrosis (Cirrhosis) 01/2020
1	Hypoxia (Hypoxemia) 04/2018
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2018
1	Residual Neoplasm 10/2017
1	B-Cell Lymphoma (Lymphoma, B Cell) 08/2015

Drug/Important Bio-Agent (IBA)

10	Proteasome InhibitorsIBA 01/2022 - 08/2015
4	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2022 - 01/2018
4	Bortezomib (Velcade)FDA Link 10/2021 - 08/2015
3	Nelfinavir (Viracept)FDA Link 01/2021 - 01/2018
3	HIV Protease InhibitorsIBA 01/2021 - 01/2018
3	carfilzomibIBA 01/2021 - 08/2015
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2021
2	Pharmaceutical PreparationsIBA 10/2021 - 07/2021
2	Cell-Free Nucleic AcidsIBA 03/2020 - 10/2017
1	ProteomeIBA 01/2022
1	ixazomibIBA 10/2021
1	melflufenIBA 07/2021
1	Peptides (Polypeptides)IBA 07/2021
1	LipidsIBA 01/2021
1	Membrane LipidsIBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2020
1	LipopolysaccharidesIBA 01/2020
1	Axl Receptor Tyrosine KinaseIBA 01/2020
1	SphingomyelinsIBA 01/2019
1	Dexamethasone (Maxidex)FDA LinkGeneric 11/2018
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 04/2018
1	Transcription Factors (Transcription Factor)IBA 04/2018
1	Lopinavir FDA Link 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 10/2017
1	Agammaglobulinaemia Tyrosine KinaseIBA 08/2015
1	ibrutinibIBA 08/2015
1	azido- Phe- Leu- Leu- 4- aminomethyl- Phe- methyl vinyl sulfoneIBA 08/2015
1	I-kappa B Proteins (I kappa B)IBA 08/2015
1	MicroRNAs (MicroRNA)IBA 01/2015
1	Circulating MicroRNAIBA 01/2015

Therapy/Procedure

3	Therapeutics 01/2021 - 01/2019